Cargando…

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation; Health Foundation Limburg BACKGROUND: The pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) is heterogeneous and incompletely understood. Identifying phenotypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Weerts, J, Achten, A, Ghossein, M, Mourmans, S G J, Barandiaran Aizpurua, A, Van Stipdonk, A M W, Vernooy, K, Prinzen, F W, Brunner-La Rocca, H P, Knackstedt, C, Van Empel, V P M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207668/
http://dx.doi.org/10.1093/europace/euad122.248
_version_ 1785046507973509120
author Weerts, J
Achten, A
Ghossein, M
Mourmans, S G J
Barandiaran Aizpurua, A
Van Stipdonk, A M W
Vernooy, K
Prinzen, F W
Brunner-La Rocca, H P
Knackstedt, C
Van Empel, V P M
author_facet Weerts, J
Achten, A
Ghossein, M
Mourmans, S G J
Barandiaran Aizpurua, A
Van Stipdonk, A M W
Vernooy, K
Prinzen, F W
Brunner-La Rocca, H P
Knackstedt, C
Van Empel, V P M
author_sort Weerts, J
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation; Health Foundation Limburg BACKGROUND: The pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) is heterogeneous and incompletely understood. Identifying phenotypes of HFpEF is a promising approach to determine the underlying pathophysiological mechanisms and to improve treatment. Patients with electrical ventricular conduction delay (VCD) may represent a separate phenotype. OBJECTIVES: To identify a VCD phenotype in HFpEF through assessment of QRS duration and vectorcardiographic QRS area. Moreover, to determine how differences in these VCD indices relate to adverse outcomes. METHODS: Consecutive patients underwent a comprehensive diagnostic work-up at baseline and were diagnosed with HFpEF. Baseline QRS duration was obtained clinically from a standard 12-leads electrocardiography (ECG). QRS area was derived from vectorcardiography analyses of the baseline ECG. Presence of VCD was categorically defined as QRS duration ≥120ms or QRS area ≥69µVs. Adverse outcome comprised a composite of HF hospitalization and cardiovascular mortality. Patients with cardiac devices before and up until one year after baseline were excluded in prognostic analyses. RESULTS: From a total of 346 HFpEF patients included in this study, 71.3% had a QRS duration <100ms compared to 20.1% with QRS duration 100-119ms and 8.6% with QRS duration ≥120ms. Only 3.8% of all patients had a QRS area ≥69µVs, indicating delayed left ventricular lateral wall activation. A history of coronary artery disease was more prevalent in patients with higher QRS duration or larger QRS area. Sex differences were mainly found in those with a QRS duration ≥100ms, which was present in 54.8% of all males and 17.5% of all females. After a median of 2 years follow-up, 16.4% of the patients had an adverse outcome. Longer QRS duration but not larger QRS area was associated with more adverse outcomes on a categorical scale (Figure). In multivariable Cox-regression analyses adjusted for sex and age, QRS duration was an independent predictor of adverse outcomes (hazard ratio per 1ms increase = 1.017, 95% confidence interval 1.004-1.030, P = 0.012) (Table). CONCLUSION: HFpEF patients have a low prevalence of a VCD phenotype, 8.6% have a QRS duration ≥120ms and 3.8% a QRS area ≥69µVs. However, QRS duration >100ms was an independent predictor for adverse outcomes. Thus, future efforts are warranted to understand the biologic and mechanical mechanisms underlying the association of QRS duration and adverse outcomes, and to determine its clinical implications. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207668
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102076682023-05-25 Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction Weerts, J Achten, A Ghossein, M Mourmans, S G J Barandiaran Aizpurua, A Van Stipdonk, A M W Vernooy, K Prinzen, F W Brunner-La Rocca, H P Knackstedt, C Van Empel, V P M Europace 12.2 - Epidemiology, Prognosis, Outcome FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation; Health Foundation Limburg BACKGROUND: The pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) is heterogeneous and incompletely understood. Identifying phenotypes of HFpEF is a promising approach to determine the underlying pathophysiological mechanisms and to improve treatment. Patients with electrical ventricular conduction delay (VCD) may represent a separate phenotype. OBJECTIVES: To identify a VCD phenotype in HFpEF through assessment of QRS duration and vectorcardiographic QRS area. Moreover, to determine how differences in these VCD indices relate to adverse outcomes. METHODS: Consecutive patients underwent a comprehensive diagnostic work-up at baseline and were diagnosed with HFpEF. Baseline QRS duration was obtained clinically from a standard 12-leads electrocardiography (ECG). QRS area was derived from vectorcardiography analyses of the baseline ECG. Presence of VCD was categorically defined as QRS duration ≥120ms or QRS area ≥69µVs. Adverse outcome comprised a composite of HF hospitalization and cardiovascular mortality. Patients with cardiac devices before and up until one year after baseline were excluded in prognostic analyses. RESULTS: From a total of 346 HFpEF patients included in this study, 71.3% had a QRS duration <100ms compared to 20.1% with QRS duration 100-119ms and 8.6% with QRS duration ≥120ms. Only 3.8% of all patients had a QRS area ≥69µVs, indicating delayed left ventricular lateral wall activation. A history of coronary artery disease was more prevalent in patients with higher QRS duration or larger QRS area. Sex differences were mainly found in those with a QRS duration ≥100ms, which was present in 54.8% of all males and 17.5% of all females. After a median of 2 years follow-up, 16.4% of the patients had an adverse outcome. Longer QRS duration but not larger QRS area was associated with more adverse outcomes on a categorical scale (Figure). In multivariable Cox-regression analyses adjusted for sex and age, QRS duration was an independent predictor of adverse outcomes (hazard ratio per 1ms increase = 1.017, 95% confidence interval 1.004-1.030, P = 0.012) (Table). CONCLUSION: HFpEF patients have a low prevalence of a VCD phenotype, 8.6% have a QRS duration ≥120ms and 3.8% a QRS area ≥69µVs. However, QRS duration >100ms was an independent predictor for adverse outcomes. Thus, future efforts are warranted to understand the biologic and mechanical mechanisms underlying the association of QRS duration and adverse outcomes, and to determine its clinical implications. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207668/ http://dx.doi.org/10.1093/europace/euad122.248 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 12.2 - Epidemiology, Prognosis, Outcome
Weerts, J
Achten, A
Ghossein, M
Mourmans, S G J
Barandiaran Aizpurua, A
Van Stipdonk, A M W
Vernooy, K
Prinzen, F W
Brunner-La Rocca, H P
Knackstedt, C
Van Empel, V P M
Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title_full Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title_fullStr Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title_full_unstemmed Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title_short Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
title_sort prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
topic 12.2 - Epidemiology, Prognosis, Outcome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207668/
http://dx.doi.org/10.1093/europace/euad122.248
work_keys_str_mv AT weertsj prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT achtena prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT ghosseinm prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT mourmanssgj prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT barandiaranaizpuruaa prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT vanstipdonkamw prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT vernooyk prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT prinzenfw prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT brunnerlaroccahp prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT knackstedtc prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction
AT vanempelvpm prevalenceandprognosticvalueofventricularconductiondelayinheartfailurewithpreservedejectionfraction